BC Week In Review | Aug 17, 2018
Clinical News

Eisai's Belviq does not increase MACE in CVOT for weight management drug

Eisai Co. Ltd. (Tokyo:4523) said Belviq lorcaserin met the primary safety endpoint by not increasing the incidence of major adverse cardiovascular events (MACE), comprising CV death, non-fatal myocardial infarction (MI) and non-fatal stroke, in the...
BC Week In Review | Aug 3, 2018
Company News

Eisai grants CY Biotech Greater China rights to lorcaserin

Eisai Co. Ltd. (Tokyo:4523) granted exclusive rights to CY Biotech Co. Ltd. (Taipei, Taiwan) to develop and market obesity drug lorcaserin (APD356) in Greater China, including Hong Kong and Macao. Under the deal, Eisai will...
BC Innovations | May 1, 2018
Distillery Therapeutics


INDICATION: Addiction Rat studies identified a carboxamide-based 5-HT2C receptor positive allosteric modulator (PAM) that could help treat cocaine addiction. Chemical synthesis and in vitro activity testing of analogs of the 5-HT2C receptor PAM lincomycin yielded...
BC Innovations | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
BC Week In Review | Jul 21, 2017
Clinical News

Phase III CAMELLIA-TIMI CVOT for Belviq ongoing

Eisai Co. Ltd. (Tokyo:4523, Tokyo, Japan) said an independent DMC recommended continuation of the Phase IIIb/IV CAMELLIA-TIMI 61 cardiovascular outcomes trial of Belviq lorcaserin (APD356) for chronic weight management. The DMC based its recommendation on...
BC Extra | Jun 1, 2017
Politics & Policy

NIH seeks public-private partnerships to fight opioid crisis

In an article published in the New England Journal of Medicine and a blog post , NIH Director Francis Collins and National Institute on Drug Abuse (NIDA) Director Nora Volkow outlined a plan to speed research...
BC Innovations | Apr 7, 2017

Pushing for progress in Prader-Willi

In the wake of the 2015 clinical failure of Zafgen Inc. ’s subcutaneous beloranib for obesity in Prader-Willi syndrome patients, the Foundation for Prader-Willi Research (FPWR) last year launched a five-year, $26 million strategic research...
BC Week In Review | Jan 6, 2017
Company News

Arena, Eisai deal

Arena amended its licensing agreement with Eisai, granting the Japanese pharma worldwide development and commercialization rights to obesity drug Belviq lorcaserin. Eisai will be responsible for all development and commercialization costs. Eisai already held rights...
BC Extra | Jan 5, 2017
Company News

Arena sells off Belviq rights

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) said it amended its licensing agreement with Eisai Co. Ltd. (Tokyo:4523), granting the Japanese pharma worldwide development and commercialization rights to obesity drug Belviq lorcaserin. Arena said Eisai will be responsible...
BC Week In Review | Dec 2, 2016
Clinical News

Ampion: Preliminary Ph I data

Preliminary data from the double-blind, placebo-controlled, U.S. Phase I AP-011 trial in 15 patients showed that a single intra-articular injection of up to 3 mL Ampion was well tolerated with no serious adverse events reported....
Items per page:
1 - 10 of 279